Israel - English - Ministry of Health

gilead sciences israel ltd - aztreonam - lyophilized powder for nebuliser solution - aztreonam 75 mg/vial - aztreonam - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

gilead sciences israel ltd - aztreonam - lyophilized powder for nebuliser solution - aztreonam 75 mg/vial - aztreonam - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

hainan hualon pharmaceutical co. ltd., china - aztreonam - powder for solution for injection - 0.5 g

European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lysine - cystic fibrosis; respiratory tract infections - antibacterials for systemic use, - cayston is indicated for the suppressive therapy of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - aztreonam - powder for solution for injection/infusion - 1 gram(s) - monobactams; aztreonam

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - aztreonam - powder for solution for injection/infusion - 2 gram(s) - monobactams; aztreonam

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aztreonam, quantity: 2.094 g - injection, powder for - excipient ingredients: arginine - aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca, citrobacter species, and serratia marcescens. lower respiratory tract infections, including pneumonia and bronchitis caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, haemophilus influenzae, proteus mirabilis, enterobacter species, and serratia marcescens. septicemia caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, serratia marcescens, and enterobacter species. skin and skin structure infections, including those associated with postoperative wounds, ulcers, and burns, caused by escherichia coli, proteus mirabilis, serratia marcescens, enterobacter species, pseudomonas aeruginosa, klebsiella pneumoniae, and citrobacter species. intra abdominal infections, including peritonitis caused by escherichia coli, klebsiella species including k. pneumoniae, enterobacter species including e. cloacae, pseudomonas aeruginosa, citrobacter species including c. freundii, and serratia species including s. marcescens. gynecologic infections, including endometritis and pelvic cellulitis caused by escherichia coli, klebsiella pneumoniae, enterobacter species including e. cloacae, and proteus mirabilis. aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. aztreonam for injection is effective against most of the commonly encountered gram negative aerobic pathogens seen in general surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aztreonam, quantity: 1.059 g - injection, powder for - excipient ingredients: arginine - aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca, citrobacter species, and serratia marcescens. lower respiratory tract infections, including pneumonia and bronchitis caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, haemophilus influenzae, proteus mirabilis, enterobacter species, and serratia marcescens. septicemia caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, serratia marcescens, and enterobacter species. skin and skin structure infections, including those associated with postoperative wounds, ulcers, and burns, caused by escherichia coli, proteus mirabilis, serratia marcescens, enterobacter species, pseudomonas aeruginosa, klebsiella pneumoniae, and citrobacter species. intra abdominal infections, including peritonitis caused by escherichia coli, klebsiella species including k. pneumoniae, enterobacter species including e. cloacae, pseudomonas aeruginosa, citrobacter species including c. freundii, and serratia species including s. marcescens. gynecologic infections, including endometritis and pelvic cellulitis caused by escherichia coli, klebsiella pneumoniae, enterobacter species including e. cloacae, and proteus mirabilis. aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. aztreonam for injection is effective against most of the commonly encountered gram negative aerobic pathogens seen in general surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - aztreonam, quantity: 75 mg - inhalation, powder for - excipient ingredients: lysine monohydrate; water for injections

Canada - English - Health Canada

gilead sciences canada inc - aztreonam - powder for solution - 75mg - aztreonam 75mg - monobactams